Finally, the new factor XIa (FXIa) inhibitors, which are being evaluated in phase III trials, may offer a new approach for AF patients with CC21: epidemiological studies have shown that while increased levels of FXI are associated with a high risk of thrombotic events, its deficiency does not increase bleeding risk.22 Here, F11 is linked to atrial fibrillation.